Holen Sie sich die Stockscreener-App
47.03
0.32%
0.15
Handel nachbörslich:
47.05
0.02
+0.04%
Moderna Inc Aktie (MRNA) Neueste Nachrichten
FDA AdCom panel to review and vote on next COVID shots - Seeking Alpha
UBS reiterates Moderna stock rating on melanoma trial catalyst - Investing.com
UBS reiterates Moderna stock rating on melanoma trial catalyst By Investing.com - Investing.com Canada
Moderna Inc. stock (US60770K1034): Vaccine player back in focus after infectious disease headline - AD HOC NEWS
Moderna, Inc. (MRNA) Stock Analysis: Navigating a Biotech Giant with a 260% Revenue Growth - DirectorsTalk Interviews
Moderna stock (US60770K1034): mRNA specialist in focus after latest quarterly figures - AD HOC NEWS
MRNA Stock Quote Price and Forecast - CNN
Moderna Inc. (NASDAQ: MRNA) Stock Under Pressure as mRNA Platform Seeks New Applications - foreignpolicyjournal.com
Moderna director Noubar Afeyan sells $433,878 in stock By Investing.com - Investing.com Australia
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in Stock - MarketBeat
Moderna director Noubar Afeyan sells $433,878 in stock - Investing.com
Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise - Stock Titan
Moderna’s mRNA flu shot to get FDA review - The Hill
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting - BioPharma Dive
Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue RulesWhat's Changed - Yahoo Finance
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm - BioSpace
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Understanding Momentum Shifts in (MRNA) - Stock Traders Daily
Total liabilities & shareholders' equities of Moderna, Inc. – BVL:MRNAUS - TradingView
ASCO26: Merck & Co., Moderna detail melanoma survival findings for cancer vaccine - FirstWord Pharma
CapEx per share of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna stock (US60770K1034): analysts turn cautious after sharp 2026 rebound - AD HOC NEWS
Moderna mRNA flu vaccine to get FDA panel review - The Hill
FDA plans rare advisory hearing to debate Moderna’s flu shot - The Boston Globe
EBITDA per share of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna, Merck cancer combo cuts melanoma spread risk at five years - Reuters
[144] Moderna, Inc. SEC Filing - Stock Titan
Moderna's mRNA flu shot to face FDA panel in June - FirstWord Pharma
Moderna Flu Shot Heads To FDA Advisory PanelModerna (NASDAQ:MRNA) - Benzinga
Moderna, Inc. Income Statement – BVL:MRNAUS - TradingView
Asset turnover of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna, Inc. Cash Flow – BVL:MRNAUS - TradingView
MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot - Yahoo Finance
Moderna (MRNA) Flu Vaccine Review Scheduled by FDA for June 2024 - GuruFocus
Moderna's (MRNA) Flu Vaccine Set for FDA Advisory Panel Review - GuruFocus
Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June - marketscreener.com
US FDA to hold expert committee meeting to review Moderna's flu vaccine - Reuters
Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports - marketscreener.com
Moderna to face FDA AdCom review for flu shot (MRNA:NASDAQ) - Seeking Alpha
FDA Plans Rare Advisory Hearing to Debate Moderna’s Flu Shot - Bloomberg.com
Forget Moderna: This biotech juggernaut is a way better buy right now - MSN
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
MRNA Stock Price, Quote & Chart | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna, Inc. Trade Ideas — LSX:A2N9D9 - TradingView
The next era of healthcare is personal - McKinsey & Company
Moderna stock (US60770K1034): Hantavirus headlines, Q1 revenue beat and lingering volatility - AD HOC NEWS
Moderna's revenues see strong international momentum in Q1 earnings - MSN
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform - BioSpace
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain - TradingView
ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position - TradingView
CHINA SHOTO : 15000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities - marketscreener.com
Moderna Inc. stock (US60770K1034): FDA path, vaccine sales and pipeline updates in focus - AD HOC NEWS
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds - The Globe and Mail
Moderna’s SWOT analysis: biotech stock faces profitability test By Investing.com - Investing.com Australia
Moderna’s SWOT analysis: biotech stock faces profitability test - Investing.com
Invesco S&P 500 Equal Weight Income Advantage ETF's Moderna Inc(MRNA) Holding History - GuruFocus
Transcript : Moderna, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 10 - marketscreener.com
MRNA: International partnerships and new vaccines fuel growth amid strong clinical and regulatory progress - TradingView
Moderna Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Moderna stock (US60770K1034): Insider sale adds to a volatile setup - AD HOC NEWS
Moderna president Stephen Hoge sells $2.58m in shares - Investing.com
Moderna (MRNA) president sells 53,336 shares after option exercises - Stock Titan
HHS rescinds vaccine panel charter citing 'administrative error' - Seeking Alpha
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):